Industry News
Biotechnology Industry News
When it comes to GSK’s new…
When it comes to GSK’s new dealmaking strategy of trying to outdo established blockbusters, CEO Luke Miels has told Fierce that oncology may offer the most tempting targets.
GSK has finally called time on its…
GSK has finally called time on its pact with Mersana Therapeutics despite sinking $100 million to secure an option for an antibody-drug conjugate (ADC).
The FDA has released briefing…
The FDA has released briefing documents detailing its concerns for AstraZeneca’s cancer drugs camizestrant and Truqap ahead of an upcoming advisory committee meeting, the first such gathering in about nine months.
The FDA today announced a new…
The FDA today announced a new initiative to allow its reviewers to access information from clinical trials in real time, with two major industry players already taking part in a pilot program.
After mulling its options for the…
After mulling its options for the past few months, Protagonist Therapeutics has decided to pocket $475 million from Takeda rather than split the U.S. profits for a near-approval hematology asset.
AbbVie has agreed to help finance…
AbbVie has agreed to help finance a KRAS inhibitor from Kestrel Therapeutics in a deal that could hit up to $1.45 billion in value and end with AbbVie buying the company outright.
Incyte’s povorcitinib has scored…
Incyte’s povorcitinib has scored a pair of phase 3 wins for a skin condition, although analysts noted the JAK inhibitor didn’t quite live up to AbbVie’s Rinvoq.
Erasca has backed up bullish…
Erasca has backed up bullish claims about its pan-RAS drug having a best-in-class profile, publishing phase 1 data that an analyst said reveal a “home run profile.”
Eli Lilly’s latest attempt to…
Eli Lilly’s latest attempt to strengthen its genetic medicine offering has seen the pharma team up with Profluent to develop AI-designed recombinases to address diseases with severe unmet needs.
Novartis is “continuing to…
Novartis is “continuing to evaluate” the in vivo CAR-T space, although the pharma’s CEO has told Fierce Biotech that no deals are currently in the works.
While the result fell short of the…
While the result fell short of the bar set by existing drugs, Boehringer is betting that targeting glucagon will make survodutide better at cutting cardiometabolic risk than incumbent products.
For Jake Becraft, Ph.D., the…
For Jake Becraft, Ph.D., the future of America’s biomedical innovation isn’t just playing out in the lab but is being shaped by industrial policy. In a recent interview with Fierce Biotech, the Strand Therapeutics CEO
After a disappointing phase 1…
After a disappointing phase 1 showing, Janux Therapeutics is kicking one of its bispecific T-cell engagers to the curb.
After launching in 2025 as a…
After launching in 2025 as a refuge for shipwrecked assets from Galapagos, Onco3R Therapeutics is rebranding as Coultreon Biopharma and filling its treasure chest with a $125 million series A.
Both Seaport and Hemab are hoping…
Both Seaport and Hemab are hoping to bring in around $180 million each from their public listings this week, in the latest sign that biotech IPOs are regaining their momentum.
Compass Therapeutics shed half its…
Compass Therapeutics shed half its stock price this morning as investors digested its bispecific antibody’s failure to hit an overall survival (OS) endpoint in a phase 2/3 study.
Astellas Pharma has done some…
Astellas Pharma has done some spring cleaning of its pipeline, dropping two phase 1 candidates and slamming the brakes on a troubled gene therapy.
Oruka Therapeutics’ long-acting…
Oruka Therapeutics’ long-acting plaque psoriasis candidate cleared the skin of 63.5% of patients in a phase 2a trial, leading Jefferies analysts to predict the asset could beat out AbbVie’s Skyrizi and generate sales of up
A phase 3 trial of Intellia…
A phase 3 trial of Intellia Therapeutics’ in vivo gene editing therapy lonvoguran ziclumeran has hit its primary endpoint, leading the biotech to start a rolling submission for FDA approval.
Eli Lilly’s run of near-weekly…
Eli Lilly’s run of near-weekly acquisitions still shows no sign of letting up, with the Big Pharma now buying Ajax Therapeutics for its clinical-stage myelofibrosis therapy.